Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2021

View Archived Issues

Selective functional impairment of HIV-specific CD8+ T cells heralds aborted HIV control

U.S. Department of Health & Human Services patents T-cell receptors against mutated RAS

New HDAC6 inhibitors identified at Chong Kun Dang Pharmaceutical

Hanyang University discovers MAPK10 inhibitors

New PDE4 inhibitors divulged by Suzhou Longbiotech Pharmaceuticals

TIMP-1 and CKM as biomarkers of therapeutic response for exon-skipping therapies in DMD

Ninjurin-1-associated eRNA linked to glioblastoma multiforme

Association between heterozygous variant in GRM1 gene and autosomal dominant cerebellar ataxia

New proteasome inhibitors show antimalarial promise

RNA therapeutic MC-30 shows efficacy in rodent models of HNSCC

Beam Therapeutics presents in vitro data on use of cytosine base editors for hepatitis B

NINDS grant supports Sinopia's IND-enabling studies of Parkinson's candidate

Targeting nigral SRY synthesis may be therapeutic for men with Parkinson's disease

Dare Bioscience awarded NICHD grant for DARE-LARC1 user-controlled contraceptive

Oblique reports in vivo data on aG13D monoclonal antibodies for colorectal cancer

Serotonin inhibition reduces tumor growth and increases CD8+ T-cell infiltration in tumor models

Diaprost licenses theranostic antibody hu5A10 to Radiopharm

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...